Steward Partners Investment Advisory LLC Sells 9,166 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Steward Partners Investment Advisory LLC cut its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 80.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,262 shares of the biotechnology company’s stock after selling 9,166 shares during the period. Steward Partners Investment Advisory LLC’s holdings in ADMA Biologics were worth $39,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund raised its position in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after acquiring an additional 700 shares during the period. Mutual of America Capital Management LLC raised its position in ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after acquiring an additional 751 shares during the period. GAMMA Investing LLC raised its position in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the period. State of Alaska Department of Revenue raised its position in ADMA Biologics by 1.0% in the fourth quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company’s stock worth $2,304,000 after acquiring an additional 1,337 shares during the period. Finally, Larson Financial Group LLC bought a new position in ADMA Biologics in the third quarter worth approximately $31,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Performance

ADMA opened at $18.71 on Wednesday. The stock has a market capitalization of $4.42 billion, a price-to-earnings ratio of 66.82 and a beta of 0.60. The company has a fifty day moving average of $16.67 and a 200 day moving average of $17.98. ADMA Biologics, Inc. has a fifty-two week low of $5.88 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.